Zoetis Inc. (NYSE:ZTS) Holdings Boosted by Venturi Wealth Management LLC

Venturi Wealth Management LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,964 shares of the company’s stock after purchasing an additional 250 shares during the quarter. Venturi Wealth Management LLC’s holdings in Zoetis were worth $1,949,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mizuho Securities USA LLC raised its holdings in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares during the last quarter. International Assets Investment Management LLC grew its holdings in Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after buying an additional 937,700 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after acquiring an additional 665,331 shares during the period. Nordea Investment Management AB boosted its position in Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares during the period. Finally, Holocene Advisors LP acquired a new position in shares of Zoetis during the third quarter valued at $110,809,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 4.5 %

Shares of ZTS opened at $157.54 on Tuesday. The company has a market capitalization of $71.08 billion, a P/E ratio of 29.61, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The business’s 50 day simple moving average is $168.51 and its 200-day simple moving average is $178.78. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. As a group, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research analyst reports. Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Barclays upped their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $214.90.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.